Evidence map›Paper›PMID 42124780›Full record

ArticleRSC chemical biology2026

Michael A Herrera, Grace K King, Zoe Ozols, Gioele A Tiburtini, Nicoletta Schiavo, Francesca Spyrakis, Louise K Charkoudian, Dominic J Campopiano

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

  • Update of
    2026
5 · Who and what money

Authors and funding

8 authors.

Michael A HerreraSchool of Chemistry, The University of Edinburgh Edinburgh EH9 3FJ UK.ORCID https://orcid.org/0009-0001-4122-1374
Grace K KingDepartment of Chemistry, Haverford College Haverford Pennsylvania 19041 USA.
Zoe OzolsDepartment of Chemistry, Haverford College Haverford Pennsylvania 19041 USA.
Gioele A TiburtiniDepartment of Drug Sciences and Technology, University of Turin Turin 10125 Italy.ORCID https://orcid.org/0009-0003-2989-4343
Nicoletta SchiavoDepartment of Drug Sciences and Technology, University of Turin Turin 10125 Italy.
Francesca SpyrakisDepartment of Drug Sciences and Technology, University of Turin Turin 10125 Italy.ORCID https://orcid.org/0000-0002-4016-227X
Louise K CharkoudianDepartment of Chemistry, Haverford College Haverford Pennsylvania 19041 USA.ORCID https://orcid.org/0000-0002-4342-2815
Dominic J CampopianoSchool of Chemistry, The University of Edinburgh Edinburgh EH9 3FJ UK.ORCID https://orcid.org/0000-0001-8573-6735

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acyl carrier proteins (ACPs) are dynamic, structurally conserved α-helical proteins central to many primary and secondary metabolic processes. Whilst prior engineering efforts have focused on strategic mutagenesis and "helix swaps", much of the ACP sequence design space remains underexplored. Here, we create diverse variants of the archetypal ACP subclass - AcpP - using a bespoke sequence-generating algorithm (ALGO-CP), which utilises a combined evolutionary and physicochemical design approach. Using ALGO-CP, we generated two soluble candidates - ALGO-055 and ALGO-059 - that can undergo full post-translational modification from

Identifiers

PMID42124780
PMCPMC13159022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.